Alkaloid-based nanodrug delivery systems: An emerging strategy against drug-resistant bacterial wound infections Authors: Jiajun Wu, Xuebo Li, Yuqi Zeng, Shenghui Hou, Nairong Yao, Bo Yang, Qiyue Yang, Xiaolin Dai Published: 2026 ABSTRACT AbstractBacterial infections significantly impede wound healing. With the escalating crisis of antimicrobial resistance, conventional antibiotics increasingly fail to meet the clinical demands for treating wounds infected with resistant strains. Plant-derived alkaloids have emerged as promising alternatives, exhibiting potent antibacterial activity, a low propensity for inducing resistance, and synergistic effects when combined with traditional antibiotics. Furthermore, they accelerate wound repair through anti-inflammatory and antioxidant mechanisms, while stimulating skin fibroblast proliferation. Despite these advantages, the clinical translation of most alkaloids is severely hindered by their low aqueous solubility and poor bioavailability. Nanodrug delivery systems (NDDS) offer a robust solution to overcome these pharmacokinetic limitations. Beyond significantly improving the targeted delivery and bioavailability of poorly soluble drugs, specific functionalized NDDS can synergistically amplify the inherent antibacterial and tissue-repairing properties of alkaloids. This review systematically evaluates the therapeutic potential and current limitations of both alkaloid monomers and alkaloid-based NDDS in infected wound management, aiming to provide a comprehensive reference for future research and clinical translation.Keywords: Alkaloid, Nanodrug delivery system, Bacteria, Wound Introduction Skin is the largest immune organ by area in the human body and serves as an important barrier that defends against bacteria, fungi, and viruses (Kwiecien et al., 2019). Due to its direct contact with the external environment; the skin is highly susceptible to injury (Han et al., 2024). In the absence of the skin's protective barrier; wounds are vulnerable to contamination and colonization by resident skin microbiota and exogenous pathogenic bacteria. This is because the exposed subcutaneous tissue provides a moist; warm; and nutrient-rich favorable microenvironment for bacterial proliferation (Chang et al., 2020; Negut et al., 2018). Bacteria proliferate extensively within wounds, secreting toxins and proteases that enhance the expression of pro-inflammatory factors and disrupt normal tissue architecture, thereby delaying wound healing (Nqoro and Taziwa, 2024). More seriously; persistent bacterial infections can lead to the formation of bacterial biofilms on the wound surface. This bacterial protective mechanism not only prolongs the infection duration; but also exacerbates tissue damage and further impedes the normal wound healing process. Prolonged infections may also lead to severe complications; such as tissue necrosis; sepsis; and may even require amputation (Pouget et al., 2022; Razdan et al., 2022; Sun et al., 2024). Chronic wounds that do not heal caused by bacterial infections impose a significant burden on global healthcare systems. Among these, in the United States alone, the annual cost of managing such wounds exceeds 96.8 billion dollars (Krishnakumar et al., 2024). In recent years; driven by population aging and the rising prevalence of chronic diseases such as obesity and diabetes; the incidence of chronic refractory wounds including diabetic ulcers; pressure ulcers and arterial venous ulcers has continued to rise. These chronic non-healing wounds markedly increase the risk of bacterial infection; further exacerbating the burden on healthcare systems (Chu et al., 2023; Pignet et al., 2024; Razdan et al., 2022). Currently, antibiotics (e.g., penicillin, vancomycin, azithromycin) remain the first-line drugs for the clinical treatment of wound infections. However, the past overuse of antibiotics has led to a significant increase in the incidence of wound infections caused by multidrug-resistant bacteria. Existing antibiotics are difficult to meet the clinical treatment needs for wounds infected with drug-resistant bacteria (Lin et al., 2025; Pont et al., 2025). Bacterial infections, especially those caused by drug-resistant bacterial strains, cause over 10 million deaths annually. (Jiang et al., 2025). However; the development of new antibiotics is costly and progresses slowly. Therefore; it is extremely urgent to explore alternative strategies for wounds infected by drug-resistant bacteria. In recent years; the antibacterial activity of plant-derived alkaloids has been extensively evaluated in biomedical research. Relevant studies have found that these alkaloids are characterized by broad-spectrum antibacterial activity and low resistance induction; and exhibit antibacterial effects against pathogenic bacteria such as Staphylococcus aureus; Pseudomonas aeruginosa; and Escherichia coli; as well as clinically common drug-resistant bacteria (e.g.; MRSA); holding great promise as an alternative to antibiotic therapy (Othman et al., 2019). In addition to their direct antibacterial effects; alkaloids can serve as antibiotic adjuvants; synergistically enhancing the antibacterial efficacy of conventional antibiotics (e.g.; penicillin; vancomycin; and gentamicin) through pathways such as downregulating bacterial resistance gene expression; inhibiting resistance enzyme activity; and disrupting biofilms (Khare et al., 2021).Furthermore; in contrast to the sole antibacterial activity of antibiotics; alkaloids also possess multiple pharmacological activities; including anti-inflammatory and antioxidant properties; which can alleviate the pathological conditions of wounds induced by bacterial infection(Bai et al., 2021; Macáková et al., 2019). Regrettably, most alkaloids face deficiencies such as low bioavailability, poor water solubility, and short half-lives in clinical applications, which severely reduce their pharmacological effects (Baldassari et al., 2023; Zhang et al., 2025c). Thanks to advances in science and technology, nanodrug delivery systems (NDDS) offer novel strategies to overcome the limitations of alkaloids in clinical applications. Currently, various advanced nano-drug carriers, such as nanoliposomes, metal-organic frameworks, cyclodextrins, self-assembled nanoparticles and exosomes, have been widely applied for the efficient delivery of alkaloids (Fig. 1). These carriers can not only improve the poor water solubility of alkaloids and prolong their duration of action, but also reduce the influence of the external environment on their biological activity. Some nanocarriers can also, through structural modification and the introduction of stimuli-responsive elements, be endowed with intelligent stimuli-responsive release properties such as pH, light and temperature-responsiveness, thereby avoiding burst drug release and reducing toxic side effects on normal tissues (Aldea-Perona et al., 2024). The synergistic effect between alkaloids and such nano-drug delivery systems can not only enhance the antibacterial activity of alkaloids, but also reduce the dosage and frequency of administration, improve patients' medication compliance, and make treatment more convenient and efficient. Novel alkaloid nanodrug delivery systems for the treatment of infected wounds. This review article systematically presents the application progress of alkaloids and their combined NDDS in the treatment of infected wounds. We first provide an overview of the pathological mechanisms underlying bacterial-mediated delayed wound healing, and subsequently elaborate on the core characteristics and advantages of alkaloids in antibacterial activity, synergistic enhancement of antibiotic efficacy, and wound healing promotion. Finally, we focus on exemplifying and analyzing the current research status, existing limitations, and future development directions of several common NDDS in combination with alkaloids for the treatment of infected wounds. It is hoped that this will provide a theoretical basis and research reference for the development of novel treatment strategies for infected wounds. Bacterial infection delays wound healing Bacterial infection, especially drug-resistant bacterial infection, is one important pathological factor leading to delayed wound healing. Its potential mechanisms mainly manifest in three aspects, namely persistent inflammatory activation, cellular function inhibition, and biofilm formation (Fig. 2). Staphylococcus aureus and Pseudomonas aeruginosa are the predominant pathogens causing wound infections (Aliakbar Ahovan et al., 2022). The virulence factors and endotoxins they secrete (e.g.; leukocidin; pyocyanin; α-hemolysin; and lipopolysaccharide); upon recognition by host cell Toll-like receptors (TLRs); activate downstream signaling pathways such as NF-κB and MAPK; produce large amounts of chemokines (e.g.; IL-8; MCP-1) that continuously recruit inflammatory cells to the wound site; and generate abundant pro-inflammatory cytokines (e.g.; IL-1; IL-6; TNF-α); thereby causing an excessive and persistent inflammatory response in the wound (Landén et al., 2016; Lu et al., 2025). Although an appropriate inflammatory response facilitates wound healing, a prolonged inflammatory state induces metabolic dysregulation in wound tissues, as evidenced by increased levels of matrix metalloproteinases (MMPs) and reactive oxygen species (ROS), thereby retarding normal wound healing (Alven and Aderibigbe, 2024). Particularly for patients with diabetic ulcers; this vicious cycle is even more pronounced. The hyperglycemic wound microenvironment can not only promote bacterial colonization and proliferation; but also further stimulate inflammatory cells via advanced glycation end products (AGEs) derived from glucose metabolism to produce inflammatory factors; ROS; and matrix metalloproteinase-9 (MMP-9); thereby damaging the extracellular matrix (ECM); weakening the tissue defense barrier; and complicating wound treatment (Hu et al., 2025b; Mahmoud et al., 2024). Moreover, these bacterial toxins inhibit the proliferation of vascular endothelial cells and fibroblasts, thereby disrupting angiogenesis and granulation tissue formation within the wound bed (Roy et al., 2020; Tran et al., 2022). While supplying adequate nutrients and oxygen to surrounding tissues, newly formed capillaries, in combination with fibroblasts, as well as type III collagen, fibronectin, hyaluronic acid and other extracellular matrix components secreted by fibroblasts, collectively constitute granulation tissue (Irma et al., 2025; Li et al., 2021b). Granulation tissue can fill the wound, provide essential structural and nutritional support for wound healing, and act as a marker of wounds entering the proliferative phase (Jiang and Scharffetter-Kochanek, 2020). When granulation tissue formation is impaired; it becomes difficult to provide adequate nutrition and scaffold support to keratinocytes; leading to impaired re-epithelialization; persistent wound opening; and elevating the risk of infection (Smith and Rai, 2024; Xu et al., 2021). Persistent wound opening creates a local microenvironment rich in necrotic tissue and cellular debris, which provides favorable conditions for bacterial adhesion, and promotes the formation of bacterial biofilms (Siddiqui and Bernstein, 2010). Biofilms are primarily composed of extracellular polymeric substances derived from bacteria-secreted polysaccharides; proteins and DNA; and adhere to the wound surface (Zhang et al., 2025a). Their adhesive properties lead to reduced neovascularization; cause local hypoxia and tissue necrosis; and exacerbate the inflammatory (Versey et al., 2021). Meanwhile; the physical barrier of biofilms hinders the penetration of inflammatory cells and antibiotics; thereby preventing thorough bacterial eradication and triggering recurrent infections (Razdan et al., 2022). More importantly; the biofilm microenvironment facilitates the horizontal transfer of plasmid-mediated resistance genes and triggers the development of bacterial monodrug and multidrug resistance; thereby attenuating antibiotic therapeutic efficacy (Cavallo et al., 2024). Overview of the Mechanism by Which Bacterial Infection Inhibits Wound Healing.Created by Biorender .com. Antibacterial mechanisms of alkaloids Alkaloids are a class of natural nitrogen-containing organic compounds widely found in microorganisms, plants and animals, which possess significant biological activities, including anticancer, antiviral and antibacterial properties (Avci et al., 2018; Habli et al., 2017). In recent years, plant-derived alkaloids have attracted widespread attention due to their outstanding advantages, such as broad antibacterial spectra, few adverse reactions, and low propensity to induce drug resistance (Table 1). As potential antibacterial agents, alkaloids can inhibit bacterial growth through multiple pathways, including inhibiting bacterial nucleic acid and protein synthesis, altering cell membrane permeability, disrupting the structures of bacterial cell membranes and cell walls, and interfering with bacterial metabolic processes (Yan et al., 2021). This multi-target synergistic action makes it difficult for bacteria to develop resistance to alkaloids through a single mutation. In addition, given the continuously increasing bacterial resistance, the use of alkaloids as antibiotic adjuvants in combination with both old and new antibiotics has also become an important research direction for combating drug-resistant bacterial infections.This chapter will focus on the antibacterial activities and activities against drug-resistant bacteria of several common alkaloids before and after their combined use with antibiotics (Fig. 3). Table 1Alkaloids possessing antibacterial properties.AlkaloidsThe structure of alkaloidsTarget MicroorganismsMICCitationBerberineImage 1Staphylococcus aureus51 μg/mL(Wu et al.; 2022)MRSA64 μg/mL(Xia et al.; 2022)Acinetobacterbaumannii256–1024 μg/mL(Zhou et al.; 2023)SanguinineImage 2MRSA3.12–6.25 μg/mL(Obiang-Obounou et al., 2011)Pseudomonas aeruginosa4–128 μg/mL(Pacyga et al.; 2024)MatrineImage 3Staphylococcus aureus25 μg/mL(Sun et al.; 2022)Escherichia coli12.5 μg/mLBacillus subtilis12.5 μg/mLPseudomonas aeruginosa25 μg/mLCandida albicans25 μg/mLCaffeineImage 4Staphylococcus aureus>16 mg/mL(Woziwodzka et al.; 2022)Pseudomonas aeruginosa>16 mg/mLAcinetobacter baumannii4 mg/mLCordycepinImage 5Escherichia coli2.5 mg/mL(Jiang et al.; 2019)Bacillus subtilis1.25 mg/mLTrigonellineImage 6Pseudomonas aeruginosa1.9 mg/mL(Kar et al.; 2024)Voacafricines A and BImage 7Staphylococcus aureus3.12 μg/mL(Ding et al.; 2018)Salmonella TyphiVoacafricines A:6.25 μg/mL、Voacafricines B:0.78 μg/mLBetaineImage 8Staphylococcus aureus7.8 μg/mL(Wijesinghe and Choo; 2022)MRSA1.56–6.25 mg/mLPseudomonas aeruginosa62.5 μg/mLReserpineImage 9Escherichia coli0.5 μg/mL(Mittal and Jaitak; 2019)ChelerythrineImage 10Bacillus subtilis1.5 μg/mL(Prachayasittikul et al.; 2013)Escherichia coli2.5 μg/mLKlebsiella pneumoniae1.5 μg/mLStreptococcus pyogene1.5 μg/mL8-hydroxy quinolineImage 11Staphylococcus aureus2 μg/mL(Houdkova et al.; 2017)Haemophilus influenzae8 μg/mLRoemerineImage 12Staphylococcus aureus32 μg/mL(Yin et al.; 2015)DihydrochelerythrineImage 13Staphylococcus aureus85.8 μM(Costa et al.; 2017)TetrandrineImage 14Staphylococcus aureus125–250 μg/mL(Lee et al.; 2012)TheophyllineImage 15Pseudomonas aeruginosa>4 mg/mL(Mohan et al.; 2024)JatrorrhizineImage 16Brucella abortus0.78 μg/mL(Azimi et al.; 2018)LysicamineImage 17Listeria monocytogenes2.5 μg/mL(Tan et al.; 2015)Streptococcus pneumoniae2.5 μg/mLStreptococcus agalactiae5 μg/mLKlebsiella pneumoniae (ESBL-KP)10 μg/mLProteus vulgaris10 μg/mLsanguinarineImage 18Staphylococcus epidermidis0.5 μg/mL(Hamoud et al.; 2015)Staphylococcus aureus (MRSA)1 μg/mLEnterococcus faecalis (Vancomycin-R)8 μg/mLEscherichia coli4 μg/mLAcinetobacter baumannii16 μg/mLKlebsiella pneumoniae16 μg/mLPalmatineImage 19Helicobacter pylori3.12 μg/mL(Rong et al.; 2016)LycorineImage 20S.aureus, B.cereus, P.aerugin, E.cloac0.24 mg/mL(Bendaif et al.; 2018)CaranineImage 21C.dubliniensis0.128 mg/mL(Ločárek et al.; 2015)StachydrineImage 22S.aureus, E.coli5 mg/mL(Taiwo et al.; 2013)Shermilamine BImage 23E.coli, M.luteus2.0–8.0 μM(Bontemps et al.; 2010)AscidideminImage 24E.coli, M.luteus0.2–0.3 μM(Bontemps et al.; 2010)ChelidonineImage 25C.albicans62.5 mg/L(Zielińska et al.; 2019)AllocryptopineImage 26S.aureus125 mg/L(Zielińska et al.; 2019)LeonurineImage 27Mycobacterium tuberculosis80 μg/mL(Cao et al.; 2023)ScopolamineImage 28Streptococcus pyogenes8 mg/mL(Tadayon et al.; 2024)Shigella dysenteriae2 mg/mL Alkaloids possessing antibacterial properties. Mechanism of antibacterial action of alkaloids. Created by Biorender.com. Berberine Berberine (BBR), an isoquinoline alkaloid derived from Ranunculaceae plants, possesses multiple pharmacological properties such as antibacterial, anti-inflammatory, antioxidant and antidiabetic activities (Miao et al., 2025; Sun et al., 2025a). In terms of antibacterial activity, BBR exerts direct inhibitory effects against Staphylococcus aureus (MIC = 51 μg/mL) and MRSA (MIC = 64–256 μg/mL) through pathways such as disrupting the integrity of the bacterial cell wall and cell membrane, reducing the accumulation of the antioxidant staphyloxanthin, and interfering with the biosynthesis of histidine and isoleucine (Wu et al., 2022; Xia et al., 2022). Furthermore, BBR can act as an antibiotic adjuvant to reduce or even reverse the drug-resistant phenotype of drug-resistant bacteria. For example, BBR directly inhibits the expression of genes related to efflux pumps (e.g., mexX, mexY, mexZ) and biofilm formation (e.g., lasI, lasR, rhlI, rhlR) in Pseudomonas aeruginosa, or competitively binds to the substrate sites of efflux pumps. Thereby, it reduces the minimum inhibitory concentrations of imipenem, azithromycin, amikacin, and gentamicin against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa by 2- to 8-fold (Zhou et al., 2023). For MRSA; Sharma et al. demonstrated that BBR binds to β-lactamase secreted by MRSA; thereby lowering the MICs of amoxicillin and ampicillin against this strain by 4- to 16-fold (Sharma et al., 2023). Sanguinine Sanguinarine (SA) is an isoquinoline alkaloid originally discovered in the rhizomes of Sanguinaria canadensis (Papaveraceae). It is often used as an animal feed additive to reduce the abundance of pathogenic microorganisms in the animal gastrointestinal tract (Croaker et al., 2016). Over the past few decades; the antibacterial and anti-inflammatory properties of SA have attracted extensive research attention. Studies have confirmed that SA exerts broad-spectrum antibacterial activity against Gram-positive and Gram-negative bacteria (Huang et al., 2024b). Against different bacterial genera; SA exhibits differential bacteriostatic mechanisms. For Staphylococcus aureus and MRSA; SA acts by disrupting the integrity of bacterial cell walls and cell membranes; promoting the efflux of sodium; potassium; calcium and magnesium ions; and thereby inducing bacterial lysis and cell death. In vitro experimental data show that the half-maximal inhibitory concentration (IC₅₀) of SA against MRSA is 3.91 μM; with a MIC ≤9.32 μM. These values are significantly superior to those of chloramphenicol used as the positive control (IC₅₀: 2.47–18.26 μM; MIC ≤58.80 μM) (Huang et al., 2024b; Qiao et al., 2024). Against Pseudomonas aeruginosa, SA specifically disrupts the functions of KguD and KguK proteins, blocks the intracellular metabolic conversion of 2-ketogluconic acid (2-KG) into 6-phosphogluconic acid, and ultimately suppresses bacterial proliferation (Falchi et al., 2021). When SA is combined with aminoglycosides; it can significantly elevate intracellular ROS levels in bacteria; leading to a 3–6 order-of-magnitude enhancement in the antibacterial efficacy of these antibiotics against Escherichia coli; Klebsiella pneumoniae; Acinetobacter baumannii; and Pseudomonas aeruginosa (Lu et al., 2022). Matrine Matrine (MT), the main bioactive component of the traditional Chinese medicine Sophora flavescens (Ku Shen), was first extracted and isolated from its root bark by Japanese researcher Nagai (Sun et al., 2022). Modern pharmacological studies have confirmed that MT exhibits significant antibacterial activity. Data from in vitro bacteriostatic experiments show that the MICs of MT against Staphylococcus aureus; Pseudomonas aeruginosa; Escherichia coli; and Bacillus subtilis are 25 μg/mL; 25 μg/mL; 12.5 μg/mL; and 12.5 μg/mL; respectively. Its bacteriostatic effect is superior to that of ciprofloxacin; a classic quinolone antibiotic (MIC: 32 μg/mL) (Jia et al., 2020). Beyond its direct bacteriostatic effect; MT also exhibits unique advantages in reversing bacterial drug resistance. The qnrS gene is the most widely distributed plasmid-mediated quinolone resistance gene. The protein encoded by this gene specifically binds to DNA gyrase; blocks the interaction between quinolone drugs and gyrase; and thereby induces bacterial drug resistance. MT can form hydrogen bonds with the QnrS protein; effectively inhibiting its activity and abrogating its protective effect on DNA gyrase. Hu et al. found that the addition of MT reduced the MIC of ciprofloxacin against Escherichia coli carrying qnrS by 4-fold (Hu et al., 2025c). Cordycepin The medicinal value of Cordyceps militaris is closely associated with cordycepin (COR), a highly active purine alkaloid present in its fruiting body. COR possesses potent immunomodulatory capacity and exerts beneficial therapeutic effects against cancer, diabetes mellitus, and hyperlipidemia (Radhi et al., 2021; Sharma et al., 2022). In recent years, relevant studies on COR have gradually expanded to its inhibitory effect on skin pathogenic bacteria (e.g., Staphylococcus aureus and MRSA) (Eiamthaworn et al., 2022). LigA is an NAD+-dependent DNA ligase essential for DNA replication; repair and recombination in Staphylococcus aureus. As an adenosine analog; COR competes with endogenous adenosine and other substrates for LigA binding. This blockade delays the repair of bacterial DNA damage and ultimately elevates bacterial mortality (Zhou et al., 2016). Penicillin-Binding Proteins (PBPs) are key players in cell wall biosynthesis and remodeling of Staphylococcus aureus. β-Lactam drugs can bind to PBPs in a targeted manner; inhibit cell wall biosynthesis; and ultimately lead to bacterial death (Carlson et al., 2025). However; Penicillin-Binding Protein 2a (PBP2a) encoded by the mecA gene in MRSA shows low affinity for β-lactam antibiotics. This allows MRSA to maintain normal cell wall biosynthesis even in the presence of antibiotics (Rocha et al., 2023). COR downregulates the transcription of the mecA gene; which reduces bacterial resistance to β-lactam antibiotics. It also exerts a direct antibacterial effect by interfering with the assembly of bacterial membrane proteins (Eiamthaworn et al., 2022). Other alkaloids In addition to the alkaloids discussed in detail above, numerous compounds, including piperine, trigonelline and caffeine, have also garnered widespread research attention in the field of antibacterial therapy. Although piperine (PIP) alone shows no significant antibacterial activity, it exerts a prominent synergistic effect when used as an adjuvant combined with antibiotics. For example, Dusane et al. demonstrated that when combined with vancomycin (MIC: 2 μg/mL) and dicloxacillin (MIC: 0.125 μg/mL), the antibacterial activity of PIP against Staphylococcus aureus was enhanced by 30% and 28%, respectively, compared with the antibiotics alone (Dusane et al., 2018). This is closely related to the fact that PIP competitively binds to the MdeA efflux pump of Staphylococcus aureus; reducing antibiotic efflux and increasing intracellular drug concentrations (Mirza et al., 2011). Trigonelline; as one of the major alkaloids in the extract from the seeds of the legume fenugreek; can inhibit the production of virulence factors in Pseudomonas aeruginosa; and interfere with its quorum sensing (QS) systems (e.g.; Las; Rhl; and Pqs pathways) in a dose-dependent manner to restrain biofilm formation; thereby exerting antibacterial and antibiofilm activities (Kar et al., 2024; Schloss et al., 2022). Another natural purine alkaloid, caffeine, has also been demonstrated to possess antibiofilm activity. Rathi et al. found that caffeine can interfere with the function of the master regulator CsgD in Escherichia coli by forming hydrogen bonds and other means, thereby inhibiting the transcription of curli-related genes csgBA and csgDEFG, blocking curli fiber synthesis, and inhibiting biofilm formation (Rathi et al., 2022). In summary, the antibacterial properties of alkaloids endow them with unique advantages and broad application prospects in promoting the healing of infected wounds, providing a potential alternative therapeutic strategy to address the increasingly serious global threat of antimicrobial resistance. Nanodrug delivery systems The particle size of nanodrug delivery systems (NDDS) typically ranges from 1 to 100 nm. Compared with larger-sized materials, nanomedicines can diffuse and transport more freely in the human body, thereby exerting therapeutic effects. Combining alkaloids with NDDS is an effective approach to optimize their pharmacokinetic properties and enhance their solubility and stability (Vanti, 2021). Moreover, some functional NDDS can also exert synergistic antibacterial effects with alkaloids, thereby improving the therapeutic efficacy of alkaloids against infected wounds. In this section, we summarize the research progress of alkaloid-based nano-delivery systems in infected wounds and discuss the unique advantages of each system. Liposome Nanoliposomes are bilayer vesicles composed of phospholipids, cholesterol and various auxiliary lipids. Structurally analogous to cell membranes, they are one of the most commonly applied nano-delivery systems (Su et al., 2018). The bilayer membrane structure of nanoliposomes enables them to simultaneously load hydrophilic and hydrophobic drugs for combined administration (Fig. 4 A) (Zununi Vahed et al., 2017). Increasing evidence indicates that liposome-based drug combinations can effectively overcome bacterial resistance and enhance the antibacterial efficacy of alkaloids.For example; Khameneh et al. employed a dehydration–rehydration method to prepare a co-loaded liposomal formulation encapsulating hydrophilic gentamicin and hydrophobic piperine (PIP). This combined formulation improved the solubility of PIP and reduced the MICs of gentamicin and PIP against MRSA by 32-fold and 100-fold; respectively; compared with their free forms; showing remarkably enhanced antibacterial activity (Khameneh et al., 2015). This dual drug-loading design exploits differences in the lipid-water partition coefficients of the drugs; which not only avoids adverse drug interactions but also enhances combined therapeutic efficacy (Hong et al., 2020). Furthermore; studies have found that liposomes; in addition to encapsulating drugs; enable their internal cholesterol to competitively bind to bacterial toxins at wound sites and protect cells from damage (Wang et al., 2025b). Inspired by this; Li et al. synthesized a BBR-loaded nanoliposomal hydrogel with a high cholesterol proportion (BH-Lip). This liposome can not only sequester bacterial pore-forming toxins and protect host cells; but also utilize the pore-forming effect of toxins to realize slow drug release and prolong drug retention time in vivo. Compared with free BBR; BH-Lip increased the inhibition rates of berberine against Staphylococcus aureus and its biofilm by 50% and 30%; respectively (Li et al., 2023).Biofilms act as a physical barrier for bacteria; enhancing their drug resistance and triggering recurrent infections. Therefore; biofilm eradication is regarded as one of the core strategies for treating infected wounds (Rothmaier et al., 2026). Chlorella pyrenoidosa (CP) is a unicellular green alga with strong biofilm penetration capacity. It can precisely deliver antibacterial drugs into the inside of biofilms; overcome the poor penetration of conventional drugs across biofilm barriers; and achieve efficient antibacterial activity.Based on this; Sun et al. combined CP with BH-Lip to construct a functionalized hydrogel; BHLip@CP; capable of actively delivering alkaloids into the interior of mature biofilms (Fig. 3 B). Under laser irradiation; CP produces abundant ROS and synergizes with BBR to effectively inhibit biofilm formation and virulence factor production of Staphylococcus aureus; and accelerate the healing of wounds infected with Staphylococcus aureus (Sun et al., 2025b). In recent years; near-infrared (NIR) light-responsive photothermal antibacterial platforms; owing to their advantages of non-invasiveness; high biosafety; strong controllability; and minimal side effects; have been considered an ideal strategy for on-demand targeted delivery of alkaloids (Gong et al., 2025). Inspired by this; Zhang et al. co-encapsulated SA and gallic acid-ferrous ion coordination nanoparticles (GA-Fe(II) NPs) into NIR-activated thermoresponsive liposomes (GA-Fe(II) NPs/SG@TSL) (Fig. 3 C). Under NIR irradiation; the photothermal effect of GA-Fe(II) NPs can not only induce a phase transition in the bilayer membrane of thermoresponsive liposomes to realize on-demand SA release; but also elevate local temperature to disrupt bacterial membrane permeability and accelerate drug penetration. In mice treated with GA-Fe(II) NPs/SG@TSL plus NIR; the MRSA survival rate at the infection site was only 1.7%; far lower than 73% in the SA group; and roughly equivalent to that of the vancomycin group.Meanwhile; this synergistic therapy also reduced the levels of pro-inflammatory cytokines TNF-α and IL-6 at the infected site by 99% and 87%; respectively; compared with the SA group; alleviating local wound inflammation (Zheng et al., 2025). This synergistic therapeutic strategy combining chemical bacteriostasis and photodynamic effects provides a feasible approach for antibiotic-free treatment of delayed wound healing caused by MRSA infection, and possesses the potential to be developed into a universal natural product delivery platform. (A). Schematic Diagram of Liposome-Mediated Drug Encapsulation. (B). Under laser irradiation, the BHLip@CP gel generatesROS, assisting BBR in effectively inhibiting the formation of Staphylococcus aureus biofilms, while promoting angiogenesis and skin regeneration to accelerate the healing of Staphylococcus aureus, infected wounds (Sun et al., 2025b). Copyright © 2025; American Chemical Society. (C). Schematic diagram of the preparation of GA-Fe(II) NPs/SG@TSL and synergistic photothermal; chemodynamic; and chemotherapeutic therapy against MRSA infection after Near-Infrared (NIR) activation (Zheng et al., 2025). This article is available under the Creative Commons CC-BY-NC-ND license and permits non-commercial use of the work as published, without adaptation or alteration provided the work is fully attributed. Metal-organic frameworks Metal-organic frameworks (MOFs) are a class of crystalline porous nanomaterials self-assembled from metal ions/clusters and organic ligands, and feature regular pore structures and high specific surface areas (Wang et al., 2025a). The composition; pore size; and specific surface area of MOFs can be flexibly regulated; allowing the fabrication of tailored carriers according to drug properties and showing great application potential in personalized medicine (He et al., 2021). Meanwhile; metal ions (e.g.; Cu; Zn; Ag) released from the degradation of some MOFs are also able to confer antibacterial activity to the material; further promoting their wide application in the fields of infected wound healing and skin regeneration (Khulood et al., 2025). Cu-MOF Copper ion (Cu2+) is a metal ion with potent bactericidal activity. Numerous studies have confirmed that Cu-MOFs exhibit broad-spectrum antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus (Aguila-Rosas et al., 2023). Meanwhile; the Cu2+ released during Cu-MOF degradation is also capable of promoting wound healing by stimulating collagen deposition and angiogenesis in wound tissues (Zhao et al., 2024b). However; excessive Cu2+ exposure can induce oxidative damage; exert toxic effects on tissues and organs; and trigger adverse reactions including hemolysis; gastrointestinal inflammation; hepatocyte necrosis; and lipid metabolism disorders (Ameh and Sayes, 2019; Wang et al., 2025c). To enhance the antibacterial efficacy of Cu-MOF and reduce the dosage of Cu2+, He et al. innovatively introduced Ag+, 4-mercaptophenylboronic acid (4-MPBA), and BBR into Cu-MOF, constructing a composite MOF with potent antibacterial properties (MOFs@Ag-B@BBR) (Fig. 5 A). In vitro antibacterial experiments confirmed that the bacterial clearance rate of the MOFs@Ag-B@BBR group against Staphylococcus aureus reached 97.71%, which was significantly higher than the 82.65% of the MOFs@Ag-B group. Besides achieving synergistic antibacterial effects, BBR incorporation also endows MOFs@Ag-B@BBR with favorable anti-inflammatory activity. This composite material can accelerate infected wound healing by down-regulating the expression of inflammatory cytokines including IL-6 and TNF-α in wound tissues. Rat wound healing assays verified that the wound closure rate of the MOFs@Ag-B@BBR + Light group reached 74.3% on day 7, which was markedly higher than the 33.91% of the control group (He et al., 2024). (A). Schematic Diagram of the Synthesis Process of MOFs@Ag-B@BBR Hydrogel and Its Antibacterial and Anti-Inflammatory Activities (He et al., 2024). © 2024 Elsevier B.V. All rights are reserved; including those for text and data mining; AI training; and similar technologies. (B). Schematic Diagram of Zn-MOFs Loaded with BBR for ROS Scavenging and Inflammation Inhibition (Hu et al., 2023). © 2023 Elsevier Ltd. All rights reserved. (C). UNB@H-Mediated BBR Delivery and ROS and Biofilm Changes Following Exposure (Mansouri et al., 2025). © 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Zn-MOF Zn2+ is an essential trace element for the human body, and has the advantages of easy availability, low cost, and environmental friendliness (Wei et al., 2022). The Zn2+ released during Zn-MOF degradation can not only exert excellent antibacterial effects by disrupting bacterial transmembrane proton transport; glycolysis and capsule integrity; but also scavenge ROS via restoring copper/zinc superoxide dismutase (Cu/Zn SOD) activity; stimulate VEGF secretion for vascularization; alleviate wound oxidative stress; facilitate angiogenesis; and accelerate wound healing (Hsu et al., 2025; Zhang et al., 2025b). Common Zn-MOFs, such as ZIF-8 (zeolitic imidazolate framework-8), IRMOF-1 and IRMOF-16, have been applied to encapsulate and deliver poorly soluble drugs, fucoidan, as well as growth factors, thereby exhibiting promising prospects for wound healing applications (Safdar Ali et al., 2021). In recent years; studies have found that the combination of Zn-MOFs and alkaloids can exert synergistic antibacterial effects; showing particularly outstanding performance in the treatment of diabetic infected wounds (Fig. 5 B). For example; Hu et al. found that the Zn2+ released during the degradation of BBR-loaded Zn-MOF can not only enhance the antibacterial efficacy of BBR by approximately 48%; but also increase the activity of Cu/Zn SOD at the wound site; inhibit the inflammatory response and the overexpression of MMP-9 in diabetic mouse wounds; and shorten the wound healing period (Hu et al., 2023). Although the antibacterial activity and drug delivery capability of Zn-MOFs have been widely recognized; traditional Zn-MOFs (e.g.; ZIF-8) possess a sodalite zeolite-type structure with small pore windows; which enables large drug molecules to adsorb only on the outer surface and thus leads to low drug loading capacity. To address this bottleneck; Zheng et al. successfully prepared hierarchical porous ZIF-8 (HZIF-8) via a template method; which effectively improves the drug loading capacity and synergistic antibacterial effect of ZIF-8. At a low concentration of 0.01 μg/mL; the inhibitory effect of BBH@HZIF-8 against Staphylococcus aureus was approximately twice that of HZIF-8 and markedly superior to free BBR. In addition; HZIF-8 also exhibited great potential as a pH-responsive drug carrier. In vitro drug release results revealed that after 24 h of incubation at pH 5.0; the cumulative BBR release rates of BBH@ZIF-8 and BBH@HZIF-8 were 84.07% and 92.07%; respectively. Furthermore; with the increase in pH; the release rate of BBH@HZIF-8 decreased to a much greater degree than that of BBH@ZIF-8. The pH-dependent release behavior of HZIF-8 inhibits the premature leakage of BBR under normal physiological conditions and prolongs the duration of drug action (Zheng et al., 2023a). Zn2+ released during Zn-MOF degradation can exert synergistic antibacterial effects with loaded alkaloid components, enhancing overall drug activity and lowering the required dosage of both agents. This multi-mechanism synergistic enhancement strategy is exactly the core mechanism by which MOF carriers markedly improve the therapeutic efficacy of alkaloids. Zr-MOF Zr4+ is an inert metal ion. Unlike MOFs assembled from heavy metal ions including Cu and Ag, which readily undergo extensive hydrolysis and ion release in acidic microenvironments to trigger oxidative stress and mitochondrial damage, Zr4+ hardly engages in cellular biochemical reactions or redox processes and presents excellent biocompatibility (Lazaro and Forgan, 2019; Raza and Wu, 2024). Among Zr-MOFs, UiO-66, synthesized from ZrCl₄ and terephthalic acid, is regarded as the prototype of the UiO subclass, and its subfamily includes UiO-67, UiO-68, MOF-801, and others. The strong Zr—O coordination bonds between zirconium and ligand oxygen atoms can resist the competitive binding of protons and metal ions to ligands, enabling these materials to maintain structural stability in acidic environments (Rosales-Pérez et al., 2023; Zhang et al., 2020a). In neutral or alkaline conditions, Zr4+ shows a higher affinity for OH−, which facilitates ligand substitution and leads to base-catalyzed hydrolysis of Zr-MOFs (Raza and Wu, 2024). Through artificial regulation; Zr-MOFs can be made to degrade only in specific acid-base environments; achieving controlled release of alkaloids. For example; after Sarker et al. introduced carboxyl (COOH) functional groups onto UiO-66; protonated caffeine (CAF) could form hydrogen bonds with the carboxylate (–COO−) groups in carboxyl-functionalized UiO-66 (UiO-66-COOH). At pH 7.4; the cumulative release rate of CAF within 12 h was only 58%; and it further slowed down with decreasing pH (Sarker and Jhung, 2019). This mechanism of achieving slow and controlled release of alkaloids based on pH differences can enable Zr-MOFs to deliver drugs at a predetermined rate according to the pH changes during the wound healing process; avoiding toxic side effects caused by burst drug release. Chronic infected wounds accumulate tissue exudate and ammonia substances from bacterial degradation of the extracellular matrix; maintaining a persistent wound pH of 7.15 to 8.90; far above the normal range of 4 to 6 (Wallace et al., 2019). This alkaline microenvironment further facilitates the colonization and biofilm formation of Staphylococcus aureus; Pseudomonas aeruginosa and other pathogens; thereby retarding wound healing (Metcalf et al., 2019). In response to wound pH variations; Mansouri et al. constructed a pH-responsive delivery system (UNB@H) based on UiO-66-NH₂ (UN) coated with hyaluronic acid to regulate BBR release (Fig. 5 C). At pH 7.4; the cumulative BBR release rates from UNB@H at 48 h and 72 h were 47.71% and 52.36%; respectively. This pattern effectively prevents the reduced therapeutic efficacy induced by the rapid metabolism of free BBR and strengthens antibacterial activity. In vitro antibacterial assays verified that the MIC of UNB@H against Staphylococcus aureus; Pseudomonas aeruginosa; and MRSA was 4–16-fold lower than that of free BBR (Mansouri et al., 2025). Compared with conventional drug delivery technologies, this nanocarrier system integrates the structural stability, pH-responsive release behavior and inherent antibacterial activity of MOFs, and provides a high-efficiency multifunctional antibacterial platform for the treatment of infected wounds. Cyclodextrin Cyclodextrins (CDs) are cyclic oligosaccharides derived from the enzymatic hydrolysis of starch. Formed by six or more glucose units connected through α-1,4-glycosidic bonds, these molecules feature a truncated cone structure and are mainly divided into three subtypes: α, β, and γ (Fig. 6 A) (Gerges et al., 2025). Cyclodextrins (CDs); as a class of classic nanoscale drug carriers; possess amphiphilicity and good biodegradability. Owing to abundant hydroxyl groups on their surfaces; CDs offer an ideal platform for molecular modification. Therefore; CDs are often used as fundamental building blocks for constructing multifunctional nano-drug delivery systems to realize controlled drug release and targeted delivery (Dai et al., 2025). (A). Schematic diagram of cyclodextrin structure. (B). Process for Preparing Polyvinyl Alcohol Nanofibres Containing BBR-Hydroxypropyl-β-Cyclodextrin Inclusion Complexes via Electrospinning (Hu et al., 2021). © 2021 Elsevier B.V. All rights reserved. (C). Schematic diagram of the pH- and temperature-dual-responsive hydrogel loaded with BBR-CD (Zhang et al., 2023b). © 2023 Published by Elsevier B.V. Among the CD family, α-CD has a relatively small cavity size, leading to limited drug inclusion capacity, while γ-CD is limited by its relatively high cost (Varan et al., 2017). By contrast; β-CD is not only easily accessible and low in preparation cost; but also has a cavity size compatible with most common drugs (Shi et al., 2025).However; β-CD also suffers from poor water solubility; it tends to precipitate in aqueous systems; which in turn induces renal injury. To address this concern; researchers have developed water-soluble derivatives such as hydroxypropyl-β-CD (HP-β-CD) and sulfobutyl ether-β-CD (SBE-β-CD) via chemical modification; and these products have become the most widely used β-CD derivatives at present (Suvarna et al., 2022). Excessive wound inflammation triggered by bacterial infection accelerates hyaluronidase synthesis; resulting in ECM degradation and delayed wound healing (Zhao et al., 2021). Stasiłowicz et al. demonstrated that the inclusion complex formed by HP-β-CD and piperine can not only protect but also further enhance piperine's antioxidant; anti-inflammatory; and hyaluronidase-inhibiting capacities. Moreover; this complex can increase the apparent permeability coefficient (Papp) of piperine by 3-fold compared with free piperine; significantly improving its transmembrane transport ability. This inclusion complex helps overcome the poor solubility and reduced biological activity of PIP; providing a theoretical basis for its application in wound healing (Stasiłowicz et al., 2021). In recent years; researchers have also tried to combine β-CD encapsulated alkaloids with wound dressings to broaden the application scope of alkaloids.As currently widely used wound dressings; electrospun nanofibrous membranes; compared with traditional dressings such as gauze and non-fibrous materials; possess high porosity. This high porosity not only facilitates water and gas permeation; but also enables the loading of various biomolecules; in turn better meeting the complex requirements of wound healing (Qu et al., 2024). For example; Hu et al. successfully prepared polyvinyl alcohol (PVA) nanofibers loaded with BBR-HP-β-CD inclusion complexes (Ber-IC) (Fig. 6 B). Compared with pure PVA nanofibers containing free BBR (PVA-BBR-NF); the in vitro release duration of BBR from PVA-Ber-IC-NF was prolonged 8-fold. Beyond providing the nanofibers with sustained and stable BBR release behavior; Ber-IC also reduced the viscosity of the spinning solution and promoted the formation of a more regular nanofiber network (Hu et al., 2021).These optimizations greatly enhanced the practical applicability of PVA-Ber-IC-NF in the field of wound dressings. Meanwhile; with the advancement of medical technology; various CD-based smart drug delivery systems (e.g.; temperature; pH; and enzyme responsive systems) have been successively developed to improve the precision of clinical treatment with alkaloid drugs (Higashi et al., 2021). Excessive inflammatory factors and bacterial metabolites at infected wound sites increase local temperature and pH. Accordingly; these two microenvironmental alterations are widely adopted as trigger signals for antibacterial drug delivery (Han et al., 2023; Zhang et al., 2021). Zhang et al. fabricated a temperature/pH dual-responsive hydrogel loaded with BBR. Its drug release behavior depends on the crosslinked network constructed by cellulose and carboxylated β-CD. Upon temperature elevation, the network chains undergo thermal contraction and reduce the resistance to drug diffusion. In addition, the alkaline wound microenvironment breaks hydrogen bonds and chemical linkages between cellulose and β-CD, loosening the network structure and synergistically facilitating drug diffusion. In vitro release tests at pH 7.6 and 40 °C revealed that BPCH-B enabled sustained BBR release for 120 h and prolonged the duration of drug action. In vivo mouse wound healing assays showed that the wound closure rate of the BPCH-B group reached 80% on day 12, which was markedly higher than the 55% observed in the control group (Fig. 6 C) (Zhang et al., 2023b). This smart responsive property based on temperature and pH variations during wound healing can not only maintain a high drug concentration in the infection phase; but also prevent adverse effects caused by excessive drug concentration in the late healing stage; further optimizing the therapeutic outcome. Conventional smart responsive drug delivery systems mostly achieve controlled drug release through the carrier's own response to the external environment; while the influence of the external environment on alkaloids is often overlooked. For example; under physiological conditions (pH 7.4); approximately 50% of SA converts into the inactive neutral form (SGOH); limiting its antibacterial efficacy. To address this issue; Kadam et al. found that the hydrophobic cavity and negatively charged sulfobutyl ether side chains of SBE-β-CD can form strong electrostatic interactions with cationic SG+. This effect effectively reduces the conversion of SG+ to SGOH and markedly elevates the proportion of its active form. In vitro experiments revealed that the antibacterial activity of this inclusion complex against Staphylococcus aureus was 2-fold higher than that of free SA (Kadam et al., 2020). Currently; both HP-β-CD and SBE-β-CD have been approved by the U.S. Food and Drug Administration as pharmaceutical excipients for oral and intravenous administration (Gao et al., 2025). With the advances in chemistry, nanotechnology and pharmaceutics, CD-based delivery systems are expected to play a vital role in the targeted delivery and clinical application of alkaloids in the future. Self-assembly Self-assembly refers to the process by which molecules spontaneously form ordered structures through non-covalent interactions, including hydrogen bonds, van der Waals forces, π-π stacking and electrostatic interactions (Fan et al., 2021). Compared with traditional nano-delivery systems; self-assembled nanocarriers have advantages such as lower toxicity; simpler preparation processes; and avoidance of potential toxicity and immunogenicity derived from carrier materials. When natural products serve as self-assembled carriers for delivering alkaloids; they play dual roles as both carriers and drugs. This not only breaks through the limitations of traditional monotherapy; but also enables synergistic treatment or enhances the efficacy of specific therapies (Lv et al., 2024; Xu et al., 2025). Currently, research on alkaloid self-assembly has mostly focused on BBR. Thus, we take BBR as a representative to overview the application of its self-assembled products in the treatment of drug-resistant bacterial infections (Guo et al., 2024).Nanoparticles self-assembled from BBR and a variety of natural products (e.g.; epigallocatechin gallate (EGCG); chlorogenic acid (CGA); cinnamic acid; baicalin; and curcumin); via π-π stacking and electrostatic interactions exhibit excellent bacterial inhibition and biofilm eradication abilities; demonstrating greater efficacy than first-line antibacterial drugs like penicillin and ciprofloxacin. Notably; different BBR-based self-assembled nanoparticles exert antibacterial effects through distinct mechanisms. For instance; the self-assembly behavior of EGCG and BBR induces the transformation of rod-shaped BBR into spherical structures with small size and good dispersibility; which makes it more likely to adhere to bacterial surfaces and disrupt bacterial structures (Fig. 7 A). In contrast; BBR-CGA self-assembled nanoparticles mainly exert antibacterial effects by downregulating the expression of genes related to biofilm; nutrient uptake; and nucleic acid metabolism in Staphylococcus aureus and MRSA; thereby affecting processes comprising bacterial biofilm formation; nutrient metabolism; and protein synthesis (Fu et al., 2024; Huang et al., 2020; Li et al., 2021a; Tian et al., 2022; Zheng et al., 2023b). Although these BBR-derived self-assembled nanoparticles exhibit antibacterial and anti-inflammatory activities, their uncontrolled and incomplete drug release limits the therapeutic efficacy in practical applications. To address the above issue, Duan et al. constructed a NIR-responsive carrier-free nanoparticle system based on BBR and indocyanine green (ICG) (BI NPs) (Fig. 7 B). Under NIR laser irradiation, the nanostructure of BI NPs is disrupted, releasing BBR and ICG. As a photosensitizer, ICG converts the light energy of NIR laser into thermal energy, which destroys bacterial cell membranes and promotes the penetration of BBR, thereby achieving a synergistic antibacterial effect. In in vitro antibacterial experiments, the antibacterial effect of the BI NPs + NIR group against Staphylococcus aureus was enhanced by approximately 56-fold compared with that of the BI NPs group (Duan et al., 2023). As a novel non-invasive therapeutic strategy; this photothermal therapy disrupts bacterial structures through local heat generation. It is not only simple to manipulate but also avoids the risk of drug-resistant bacteria emergence (Huang et al., 2024a). (A). Schematic representation of the self-assembly and antibacterial mechanism of BBR-EGCG nanoparticles (Zheng et al., 2023b). (B). Schematic diagram of the preparation of BI NPs; their controlled release under NIR light irradiation; and their promotion of the healing of Staphylococcus aureus infected wounds (Duan et al., 2023). (C). The mechanism of controlled release of BBR-EGCG NPs coated with MnO₂ NSs and GOX under NIR light irradiation and their promotion of the healing of infected diabetic wounds (Zhang et al., 2024b). © 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. During wound healing, alongside reducing the risk of bacterial infection, stimulating local cell proliferation at the wound site is equally critical. Severe bacterial infection can trigger local wound ischemia. Insufficient blood perfusion disrupts the delivery of nutrients and metabolites, prolongs inflammatory infiltration, delays wound repair, and exacerbates infection-associated complications, ultimately creating a vicious cycle (Li et al., 2024; Yang et al., 2025). Therefore, the development of novel drugs or formulations that simultaneously possess the capabilities of controlling bacterial infection and promoting angiogenesis has become one of the important directions in research on promoting wound healing (Veith et al., 2019). Wang et al. provided an effective strategy to address this challenge by developing a BA-SA hydrogel system formed through the self-assembly of baicalin (BA) and SA. This hydrogel not only inhibits the proliferation of MRSA to alleviate inflammatory responses in infected wounds but also accelerates angiogenesis and collagen deposition through coordinated mechanisms such as upregulating VEGF expression and promoting granulation tissue formation; thereby driving the wound into the proliferation and remodeling phases more rapidly. In a full-thickness MRSA-infected mouse wound model; the BA-SAN gel significantly enhanced wound healing; achieving a healing rate of 87.49 ± 5.25% on day 12; outperforming both the MRSA-infected group (70.19 ± 3.97%) and the control group (72.63 ± 2.58%) (Wang et al., 2023). Furthermore; excessive inflammation and oxidative stress are also among the dominant factors contributing to delayed wound healing; particularly the prolonged healing of diabetic wounds (Li et al., 2019). Therefore; the application of anti-inflammatory and antioxidant drugs in diabetic wound management is of great significance. Shaik et al. investigated the potential role of the nanoconjugate COR-MEL; which is constructed from cordycepin (COR) and melittin (MEL); in inhibiting inflammation and oxidative stress in diabetic wounds. This nanoconjugate creates a suitable microenvironment for wound repair by downregulating the expression levels of the inflammatory factors IL-6 and TNF-α; while simultaneously increasing the activities of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx). In vivo experimental results showed that the wounds of diabetic rats treated with COR-MEL were nearly completely healed 14 days after administration; whereas the groups treated with COR or MEL alone had a wound closure rate of only 69%–75% (Shaik et al., 2023). Now, researchers have clearly recognized that the key factor behind delayed wound healing in diabetes is a cascade of reactions triggered by hyperglycemia.Merely inhibiting bacterial infection, controlling the inflammatory response, and reducing oxidative stress often yield suboptimal outcomes (Huang et al., 2024c; Wang et al., 2024). To alleviate the hyperglycemic microenvironment of diabetic wounds, Zhang et al. innovatively synthesized manganese dioxide nanoshells (MnO₂ NSs) in-situ on the surface of BBR-EGCG NPs, and loaded glucose oxidase (GOX) to form a protein corona, thereby constructing BBR-EGCG@MnO₂@GOX nanoparticles (BEMGNPs) (Fig. 7 C). GOX on the surface of BEMGNPs can specifically catalyze glucose to generate gluconic acid and hydrogen peroxide (H₂O₂), which reduces local blood glucose levels at the wound site. The generated H₂O₂ is decomposed by MnO₂ NSs to produce oxygen (O₂), which further forms local oxygen therapy. This system synergistically accelerates fibroblast migration, epithelial cell proliferation, and neovascularization together with BBR-EGCG NPs (Zhang et al., 2024b). With the development of technology, the combination of self-assembled drugs and multifunctional carriers may become an important breakthrough point in the field of wound therapy. With the continuous advancement of research, the self-assembled integration of alkaloids and other natural products is expected to serve as a key breakthrough in the management of infected wounds. Exosomes Exosomes (Exos) are a class of natural nano-sized lipid bilayer vesicles secreted by various types of cells, with a wide range of sources, and can be divided into two major categories, namely animal-derived and plant-derived (Fig. 8 A) (Zhang et al., 2020b). Compared with synthetic delivery vectors; exosomes exhibit favorable biodistribution; high stability and diverse loading strategies. Furthermore; as cell-secreted spontaneous vesicles; exosome membranes are embedded with bioactive proteins from donor cells; which enables active targeting to specific receptors. This distinctive property grants exosomes prominent superiority in targeted drug delivery (Kimiz-Gebologlu and Oncel, 2022; Modani et al., 2021). (A). Schematic diagram of the structure of exosomes. (B). Schematic diagram of engineered exosome structure. (C). Schematic diagram of the preparation process of kelp-derived exosomes loaded with caffeic acid and their acceleration of diabetic wound healing in combination with conductive microneedles (Liu et al., 2025). © 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH. Given that exosomes (Exos) feature potent cellular barrier penetration, favorable drug loading capacity and inherent tissue-homing properties, researchers have integrated alkaloids with Exos to advance wound healing and satisfy the multiple demands of wound management, and have achieved favorable therapeutic efficacy (Ding et al., 2023; Joorabloo and Liu, 2023). For example, Zhang et al. found that matrine-loaded human skin fibroblast exosomes (MHEM) exert multi-mechanism synergistic effects, including inhibiting ROS production in M1 macrophages, promoting ordered ECM synthesis, and accelerating tissue regeneration and vascularization. This treatment reduces scar formation across three key stages of wound healing, namely inflammation, proliferation, and blood supply restoration. It ultimately realizes functional wound repair rather than scar repair. Compared with the control groups treated with matrine alone or exosomes alone, the wound healing time in the MHEM group was shortened by approximately 20%–30% (Zhang et al., 2024c). In contrast to animal-derived exosomes; which are limited by low yield and difficult isolation and are prone to carrying zoonotic pathogens and carcinogenic signals; plant-derived extracellular vesicles (EVs) can be abundantly obtained from plant tissues such as fruits and vegetables and pose no risk of carrying the above pathogens (Dad et al., 2021; Zhao et al., 2024a). Furthermore, by engineering EVs through biological, immunological, physical and chemical modification (Fig. 8 B), researchers can further improve their targeting capability and drug loading capacity, and achieve controlled drug release (Zhang et al., 2023a). Therefore; in recent years; researchers have begun to explore the application of EVs in wound repair. Although direct evidence regarding the use of EVs as carriers for alkaloid delivery in wound healing remains insufficient; relevant studies can provide valuable references for future research. For example; Liu et al. used a co-incubation method to load poorly soluble caffeic acid into kelp-derived EVs; which were then incorporated into conductive microneedles to achieve controlled CA release via electrical stimulation (Fig. 8 C). In vitro wound healing experiments showed that the wound healing rate of the experimental group (95.61% ± 0.49%) was significantly higher than that of the EVs-only group (81.75% ± 0.44%) (Liu et al., 2025). Based on the above findings, further exploration of the feasibility of using EVs as delivery carriers for alkaloids is expected to offer a novel strategy for the treatment of infected wounds. Other nanodrug delivery systems In addition to the several delivery carriers highlighted in the above studies, various composite nano-delivery systems have also shown great application potential in alkaloid delivery. This section briefly introduces several representative systems. Excessively high loading levels of hydrophobic alkaloids may compromise the structural stability of liposomes and trigger premature drug release. To solve this issue, McCormack and Gregoriadis developed a composite DCL system, whereby the drug is first loaded into cyclodextrin (CD) and then encapsulated within liposomes (Azzi et al., 2018; Olofinsan et al., 2023). Cyclodextrin encapsulation of hydrophobic alkaloids in DCL can effectively inhibit drug aggregation. Meanwhile, the outer liposomal coating can also alleviate adverse effects resulting from the overuse of free CD. Although direct evidence for the application of DCL loaded with alkaloids in the treatment of infected wounds is currently insufficient, relevant studies have confirmed that DCL encapsulated with alkaloids such as camptothecin and vinblastine for cancer treatment can prolong drug half-life, reduce toxicity to normal cells, and markedly enhance anticancer efficacy (Feng et al., 2024). In addition to the formation of DCL with liposomes; CD-MOFs fabricated by coordinating cyclodextrin with alkali metal cations (e.g.; K+) can not only enhance the solubility of alkaloids but also improve their stability via distinctive cavity structures and internal voids (Shen et al., 2021; Si et al., 2024). For example, Marak et al. found that β-CD-MOF can not only enhance the solubility of piperine, but also preserve its biological activity against changes in pH, temperature and ionic conditions during processing. Even after storage at 30 °C for three months, the antioxidant activity of piperine exhibited no significant loss (Marak et al., 2025). MXene; a typical two-dimensional material composed of transition metal carbides; nitrides; or carbonitrides; can not only serve as a drug delivery carrier but also exhibit excellent photothermal performance. Under near-infrared irradiation; MXene can efficiently convert light energy into heat; thereby enabling effective bacterial ablation (Deng et al., 2025; Hu et al., 2025a). Inspired by this, Zhang et al. fabricated NIR-responsive MXene modified with an ammonium phosphate zwitterionic material (AHEP@Ta₄C₃) and used it as a carrier for SA. In vitro antibacterial experiments showed that the inhibitory rate of the SAN@AHEP@Ta₄C₃ + NIR group against Staphylococcus aureus reached approximately 90%, far higher than the 60% for free SA (Zhang et al., 2024a). Such composite carriers integrate the merits of diverse nano-delivery systems, and are expected to break through multiple bottlenecks in the clinical translation of alkaloids and promote their development toward precise therapy. Discussion Overall, the antibacterial potential of alkaloids, whether used alone or as antibiotic adjuvants, has been well confirmed. In the face of the growing antibiotic resistance crisis, in addition to vigorously screening novel antibiotics, alternative intervention strategies to overcome bacterial resistance can also be explored. An in-depth analysis of the antibacterial effects and mechanisms of alkaloids is expected to inspire and promote the development of novel antibacterial drugs with high efficacy, broad spectrum, low toxicity, and low resistance induction tendency. At present, some plant-derived alkaloids have already been used as lead compounds for the development of novel antibacterial drugs. For instance, via nucleophilic substitution, Hao et al. covalently linked BBR with canagliflozin, an antidiabetic drug with potential antibacterial activity. The synthesized compound BC showed antibacterial activity approximately 2.3–4.2 times higher than that of free BBR (Hao et al., 2022). Although there is currently a lack of clinical drugs that directly utilize alkaloids or their derivatives for the treatment of infected wounds; some plant-derived quinoline alkaloid derivatives have been successfully commercialized and applied in the clinical treatment of bacterial infections. For example; nitroxoline has been used for the treatment of urinary tract infections in Europe and Asia (Cherdtrakulkiat et al., 2016). Another quinoline derivative; bedaquiline; has also been approved in the United States for the treatment of multidrug-resistant tuberculosis (Fox and Menzies, 2013). To overcome the drawbacks of alkaloids, including poor solubility, low stability and weak targeting ability, encapsulating them in nanocarriers such as liposomes and cyclodextrins can effectively enhance their solubility and bioavailability. Moreover, through structural modification, these NDDS can be endowed with stimuli-responsive properties, enabling controlled release of alkaloids and prolonging the duration of drug efficacy. However, such traditional nanocarriers possess relatively insufficient targeting ability and cannot efficiently accumulate at wound inflammatory sites. Therefore, exosome-based nano-delivery strategies have emerged. Benefiting from the homing properties endowed by their surface proteins, exosomes can actively target inflammatory sites, thereby overcoming the limitations of passive targeting of traditional nanocarriers. Furthermore, MOFs constructed with metal ions such as Cu2+ and Zn2+ as frameworks can not only act as drug carriers, but also exert intrinsic broad-spectrum antibacterial activity to generate synergistic effects with loaded alkaloids, thereby improving wound healing efficacy. As a complement to the aforementioned exogenous carrier strategies, the self-assembly-based carrier-free nano-delivery system opens up a new path. It utilizes the structural characteristics of alkaloid molecules such as hydrophobic groups and hydrogen bonding sites to form nanoparticles through non-covalent interactions. This strategy not only achieves nearly 100% drug encapsulation efficiency, but also fundamentally circumvents the risks of immune rejection and toxicity accumulation that may be caused by exogenous carriers. It provides a new pathway for the safe application of alkaloids in the treatment of infected wounds. Although alkaloid-based NDDS hold great potential in the field of wound healing, their clinical translation still faces multiple challenges. First, NDDSs may exhibit certain cytotoxicity at high concentrations. For example, although the antibacterial metal ions released during MOF degradation can exert synergistic antibacterial effects with alkaloids, they also pose the risk of heavy metal poisoning. To address such challenges, in addition to applying biocompatible materials to reduce their toxicity, it is more necessary to elucidate the in vivo degradation, metabolism, and clearance mechanisms of NDDS, and to establish and optimize relevant toxicity screening and evaluation criteria. Second, although most NDDS possess stimuli-responsiveness and on-demand drug release properties, some endogenous stimuli are not wound-specific, which may lead to premature drug release and off-target effects. Therefore, in-depth fundamental research is needed to develop more precise delivery strategies, enabling alkaloids to be released at the optimal time to match the unique microenvironment of infected wounds. Third, NDDS represented by exosomes have limitations such as low isolation and purification yield, high production cost, and difficulty in large-scale production. To overcome these bottlenecks, in addition to cultivating engineered cells capable of stable and high-yield exosome production, it is also necessary to innovate isolation and purification technologies and promote the shift of exosomes from laboratory-scale fine preparation to industrial large-scale supply, thereby achieving clinical popularization and industrialization. Moreover, the combined application of antibiotics and alkaloids should not be overlooked. In the future, co-delivery strategies employing alkaloids as adjuvants in combination with traditional antibiotics are expected to overcome the limitations of monotherapy, providing an efficient and safe novel option for the clinical treatment of chronic and drug-resistant bacterially infected wounds. Finally, most current studies on alkaloids and their NDDS in the treatment of infected wounds are in vitro experiments, and clinical research remains relatively scarce. However, NDDS represented by liposomes and CDs have already formed a relatively complete technical system and clinical evidence chain in the field of alkaloid drug loading, and have been approved for the clinical treatment of diseases such as liver cancer, lung cancer, and breast cancer. The clinical application of these alkaloid formulations not only validates the feasibility of liposomes and CDs as carriers for alkaloids, but also lays a solid theoretical foundation for their subsequent clinical translation into infected wound treatment. Conclusion In summary, alkaloid-based nano-formulations have achieved substantial progress in promoting the healing of infected wounds. Although their clinical translation still faces many challenges, with the continuous development of nanotechnology, these problems are expected to be gradually resolved. In the future, combining such formulations with wound dressings such as hydrogels and nanofiber sheets is expected to further expand their clinical application scenarios, achieve local efficient delivery and controlled release of alkaloids, and thereby accelerate the repair process of infected wounds. It is hoped that this review may provide a useful reference and impetus for the development of alkaloid-based NDDS strategies for wound management. CRediT authorship contribution statement Jiajun Wu: Writing – original draft, Methodology, Formal analysis. Xuebo Li: Writing – original draft, Methodology. Yuqi Zeng: Resources, Funding acquisition. Shenghui Hou: Methodology, Formal analysis. Nairong Yao: Supervision, Funding acquisition. Bo Yang: Supervision, Resources, Funding acquisition. Qiyue Yang: Supervision, Methodology. Xiaolin Dai: Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgements The work was supported by Chengdu Science and Technology Project–Key R&D Support Program (Grant No. 2024-YF05-02677-SN), Sichuan Medical Research Program (Grant No. S23074) and Beijing Medical Award Foundation Research Program (Grant No. YXJL-2025-0106-0104). Contributor Information Qiyue Yang, Email: ruozi0920@163.com. Xiaolin Dai, Email: daixiaolin333@163.com. Data availability No data was used for the research described in the article. References Associated Data Data Availability Statement No data was used for the research described in the article.